S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:ZNTL

Zentalis Pharmaceuticals (ZNTL) Stock Price, News & Analysis

$15.76
+0.57 (+3.75%)
(As of 03/28/2024 ET)
Today's Range
$15.22
$16.08
50-Day Range
$10.83
$15.49
52-Week Range
$9.56
$31.46
Volume
577,810 shs
Average Volume
825,149 shs
Market Capitalization
$1.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.57

Zentalis Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
143.2% Upside
$38.57 Price Target
Short Interest
Bearish
23.59% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.81mentions of Zentalis Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$42,854 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.72) to ($3.78) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.95 out of 5 stars

Medical Sector

845th out of 938 stocks

Pharmaceutical Preparations Industry

390th out of 433 stocks

ZNTL stock logo

About Zentalis Pharmaceuticals Stock (NASDAQ:ZNTL)

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

ZNTL Stock Price History

ZNTL Stock News Headlines

ZNTL Jul 2024 12.500 call
How you can target big results without spending big money!
While most folks are paying $500… $1,000… Or even MORE to trade popular stocks like Apple, Nvidia, or Microsoft… I’ve discovered a new way to tap into what could be the cheapest options on the market… I’m talking about the $0.25 Cent Trades!
ZNTL Jul 2024 10.000 call
Zentalis Pharmaceuticals, Inc.
Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
Oppenheimer Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)
TD Cowen Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)
Zentalis Pharmaceuticals Inc Ordinary Shares
See More Headlines
Receive ZNTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zentalis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ZNTL
Fax
N/A
Employees
124
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$38.57
High Stock Price Target
$70.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+143.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-292,190,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.18 per share

Miscellaneous

Free Float
66,631,000
Market Cap
$1.13 billion
Optionable
Optionable
Beta
1.72
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Kimberly Lynn Blackwell M.D. (Age 54)
    CEO & Director
    Comp: $1.12M
  • Mr. Cameron S. Gallagher M.B.A. (Age 53)
    Co-Founder, President & Director
    Comp: $767.69k
  • Ms. Melissa B. Epperly M.B.A.Ms. Melissa B. Epperly M.B.A. (Age 45)
    CFO & Treasurer
    Comp: $721.64k
  • Ms. Andrea Paul J.D. (Age 42)
    Chief Legal Officer & Corporate Secretary
    Comp: $668.2k
  • Dr. Mark Lackner Ph.D. (Age 56)
    Chief Scientific Officer
  • Dr. Diana F. Hausman M.D. (Age 61)
    Chief Medical Officer & Director
  • Ms. Kimberly Freeman
    Chief Strategy Officer
  • Dr. Kyle Rasbach Ph.D. (Age 44)
    Pharm.D., Chief Business Officer
  • Dr. Adrian Jubb M.D.
    Ph.D., Executive Vice President of Clinical Development

ZNTL Stock Analysis - Frequently Asked Questions

Should I buy or sell Zentalis Pharmaceuticals stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zentalis Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ZNTL shares.
View ZNTL analyst ratings
or view top-rated stocks.

What is Zentalis Pharmaceuticals' stock price target for 2024?

7 Wall Street research analysts have issued 1-year price objectives for Zentalis Pharmaceuticals' shares. Their ZNTL share price targets range from $15.00 to $70.00. On average, they anticipate the company's stock price to reach $38.57 in the next year. This suggests a possible upside of 143.2% from the stock's current price.
View analysts price targets for ZNTL
or view top-rated stocks among Wall Street analysts.

How have ZNTL shares performed in 2024?

Zentalis Pharmaceuticals' stock was trading at $15.15 on January 1st, 2024. Since then, ZNTL shares have increased by 4.7% and is now trading at $15.86.
View the best growth stocks for 2024 here
.

When is Zentalis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our ZNTL earnings forecast
.

How were Zentalis Pharmaceuticals' earnings last quarter?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) issued its quarterly earnings data on Tuesday, February, 27th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.92) by $0.09.

What ETFs hold Zentalis Pharmaceuticals' stock?

ETFs with the largest weight of Zentalis Pharmaceuticals (NASDAQ:ZNTL) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and ALPS Medical Breakthroughs ETF (SBIO).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of Zentalis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zentalis Pharmaceuticals investors own include Esperion Therapeutics (ESPR), Zogenix (ZGNX), AbbVie (ABBV), Advanced Micro Devices (AMD), BioMarin Pharmaceutical (BMRN), Bristol-Myers Squibb (BMY), Clovis Oncology (CLVS), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK) and Phillips 66 (PSX).

When did Zentalis Pharmaceuticals IPO?

Zentalis Pharmaceuticals (ZNTL) raised $131 million in an initial public offering on Friday, April 3rd 2020. The company issued 7,700,000 shares at $16.00-$18.00 per share. Morgan Stanley, Jefferies, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO.

Who are Zentalis Pharmaceuticals' major shareholders?

Zentalis Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Eventide Asset Management LLC (16.29%), Vanguard Group Inc. (7.56%), Vanguard Group Inc. (7.54%), Price T Rowe Associates Inc. MD (4.10%), Price T Rowe Associates Inc. MD (4.09%) and Capital International Investors (3.98%). Insiders that own company stock include Alexis Pinto, Anthony Y Sun, Cam Gallagher, Carrie Brownstein, David Michael Johnson, Dimitris Voliotis, Jan Skvarka, Kevin D Bunker, Kevin D Bunker, Kimberly Blackwell, Matrix Capital Management Comp and Melissa B Epperly.
View institutional ownership trends
.

How do I buy shares of Zentalis Pharmaceuticals?

Shares of ZNTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ZNTL) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners